For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc.…
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to come up…
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones Industrial Average components, appears to be undergoing a bit of change for…
Throughout December we have been giving updates on dividends that will rise in the coming days and weeks from the 30 Dow Jones Industrial Average stocks. Many have already come true and…
Spending on advertising barely showed a pulse in the third quarter of 2011, growing by just 0.4%, according a report from Kantar Media cited in The New York Times. Spending growth has…
Congress, close to a budget agreement, may avoid a government shutdown. (Reuters) Washington Mutual shareholders and creditors set a deal that could allow an exit from bankruptcy. (Reuters) The policy meeting of…
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead. Among those we expect to raise the dividend is…
S&P may downgrade the EU and the largest eurozone banks. (Reuters) France and Germany continue to press new eurozone treaty measures that would help trigger new financing for the region. (Reuters) Japan says…
Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company (NYSE: DIS) joined in on the dividend hike brigade with another dividend…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has had its share of trouble in 2011, but perhaps the expiring patent on that statin Lipitor by Pfizer Inc. (NYSE: PFE) may offer some reprieve. …
It has been a long time coming, and now many patients will be able to switch to a generic. Pfizer Inc. (NYSE: PFE) has now officially lost its patent over its cholesterol-lowering…
The EU continues to work on its bailout fund and may ask the IMF for help. (Reuters) American Airlines parent AMR (NYSE: AMR) files for Chapter 11. (Reuters) S&P cuts its ratings on…
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic versions of…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie…
The supercommittee appears unlikely to settle on a deficit agreement. (Reuters) A senior Chinese official says he expects the global recession to last for some time. (Reuters) Spain’s center-right People’s Party gains…
